LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management Guidelines.

    Andole, Sowmya / Senthil, Sirisha

    Seminars in ophthalmology

    2022  Volume 38, Issue 2, Page(s) 158–166

    Abstract: Purpose: Assessment of ocular surface in patients using anti-glaucoma medications (AGM) is rarely a priority for clinicians since glaucoma management targets intraocular pressure and preserves vision. This review summarizes the various adverse effects ... ...

    Abstract Purpose: Assessment of ocular surface in patients using anti-glaucoma medications (AGM) is rarely a priority for clinicians since glaucoma management targets intraocular pressure and preserves vision. This review summarizes the various adverse effects of topical AGM on the ocular surface and highlights the importance of ocular surface assessment in these patients.
    Methods: A literature search of articles (English only) on the subject matter was conducted focusing on recent articles published in the past 5 years.
    Results: The use of multiple anti-glaucoma medications in glaucoma patients increases patients' exposure to the drug and the preservatives present in these medications. Long-term use of these medications has deleterious effects on the conjunctiva, cornea, eyelids, and periocular tissues like trichiasis, entropion, symblepharon, forniceal shortening, punctate keratopathy, non-healing epithelial defects, and pannus. Treatment requires drug withdrawal or substitution by oral or topical non-preserved and less toxic preparations of AGMs. The ocular surface and symptoms can improve if the condition is diagnosed early and after drug withdrawal in over 90% of eyes. However, stopping or changing AGMs can often present with its own unique set of challenges in intra-ocular pressure control which may often need glaucoma surgery in close to 20% of eyes for IOP control.
    Conclusion: Topical antiglaucoma medications (with their preservatives) can induce severe ocular surface and periorbital changes. Early identification and withdrawal of the offending drug/preservative can help to reverse the changes except in eyes with extensive cicatrization.
    MeSH term(s) Humans ; Antiglaucoma Agents ; Antihypertensive Agents/adverse effects ; Glaucoma/diagnosis ; Glaucoma/drug therapy ; Intraocular Pressure ; Eyelids ; Preservatives, Pharmaceutical/adverse effects
    Chemical Substances Antiglaucoma Agents ; Antihypertensive Agents ; Preservatives, Pharmaceutical
    Language English
    Publishing date 2022-08-01
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 632820-9
    ISSN 1744-5205 ; 0882-0538
    ISSN (online) 1744-5205
    ISSN 0882-0538
    DOI 10.1080/08820538.2022.2094714
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Field-based 3D-QSAR for tyrosine protein kinase JAK-2 inhibitors.

    Andole, Sowmya / Thumma, Gouthami / Alavala, Rajasekhar Reddy / Gangarapu, Kiran

    Journal of biomolecular structure & dynamics

    2023  , Page(s) 1–13

    Abstract: The present work aimed to develop a Field-based 3D-QSAR model with existing JAK-2 inhibitors. The JAK-STAT pathway is known to play a role in the development of autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and Crohn's disease. ...

    Abstract The present work aimed to develop a Field-based 3D-QSAR model with existing JAK-2 inhibitors. The JAK-STAT pathway is known to play a role in the development of autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Dysregulation of JAK-STAT is also linked to the development of myelofibrosis and other myeloproliferative diseases. JAK antagonists can be used in many areas of medicine. There are many compounds that already show inhibition of Jak-2. We have developed a Field-based 3D QSAR model which showed good correlation values (
    Language English
    Publishing date 2023-07-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 49157-3
    ISSN 1538-0254 ; 0739-1102
    ISSN (online) 1538-0254
    ISSN 0739-1102
    DOI 10.1080/07391102.2023.2226723
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: 3D QSAR based Virtual Screening of Flavonoids as Acetylcholinesterase Inhibitors.

    Andole, Sowmya / Sd, Husna / Sudhula, Srija / Vislavath, Lavanya / Boyina, Hemanth Kumar / Gangarapu, Kiran / Bakshi, Vasudha / Devarakonda, Krishna Prasad

    Advances in experimental medicine and biology

    2023  Volume 1424, Page(s) 233–240

    Abstract: In an attempt to develop therapeutic agents to treat Alzheimer's disease, a series of flavonoid analogues were collected, which already had established acetylcholinesterase (AChE) enzyme inhibition activity. For each molecule we also collected biological ...

    Abstract In an attempt to develop therapeutic agents to treat Alzheimer's disease, a series of flavonoid analogues were collected, which already had established acetylcholinesterase (AChE) enzyme inhibition activity. For each molecule we also collected biological activity data (Ki). Then, 3D-QSAR (quantitative structure-activity relationship model) was developed which showed acceptable predictive and descriptive capability as represented by standard statistical parameters r2 and q2. This SAR data can explain the key descriptors which can be related to AChE inhibitory activity. Using the QSAR model, pharmacophores were developed based on which, virtual screening was done and a dataset was obtained which loaded as a prediction set to fit the developed QSAR model. Top 10 compounds fitting the QSAR model were subjected to molecular docking. CHEMBL1718051 was found to be the lead compound. This study is offering an example of a computationally-driven tool for prioritisation and discovery of probable AChE inhibitors. Further, in vivo and in vitro testing will show its therapeutic potential.
    MeSH term(s) Cholinesterase Inhibitors/pharmacology ; Cholinesterase Inhibitors/therapeutic use ; Quantitative Structure-Activity Relationship ; Flavonoids/pharmacology ; Molecular Docking Simulation ; Acetylcholinesterase/metabolism
    Chemical Substances Cholinesterase Inhibitors ; Flavonoids ; Acetylcholinesterase (EC 3.1.1.7)
    Language English
    Publishing date 2023-07-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 410187-X
    ISSN 0065-2598
    ISSN 0065-2598
    DOI 10.1007/978-3-031-31982-2_26
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top